1
|
Fetter A, Gilboy M. Addressing Food Insecurity on College Campuses: The Food Pantry and Beyond. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.08.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
2
|
Busby LT, Sheth S, Garey J, Ginsburg A, Flynn T, Willen MA, Kruger S, Neubauer MA, Kolodziej M, Chang D, Palmer ES, McGuinness M, Egerton NJ, Merriman J, Herbeck EB, Fetter A, Frisk L, Sitarik M, Anderson R, Beveridge R. Creating a process to standardize regimen order sets within an electronic health record. J Oncol Pract 2011; 7:e8-e14. [PMID: 22043198 PMCID: PMC3140457 DOI: 10.1200/jop.2011.000275] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/26/2011] [Indexed: 11/20/2022] Open
Abstract
PURPOSE US Oncology uses regimen order sets in clinical practice to treat patients. However, the process to assure accuracy and upkeep of these order sets has not been described. The purpose of this project was to evaluate the regimens housed in the electronic health record, iKnowMed, to determine their appropriateness and accuracy. MATERIALS AND METHODS US Oncology conducted an audit of its standardized regimen library. A utilization review compared chemotherapy regimens in the library and consolidated order sets on the basis of past utilization. Next, internal and external clinical pharmacists were contracted to verify the accuracy, dose, duration, and cycle length of regimens. References cited in the regimen library were evaluated. New or updated references or clinical practice standards were added or modified when necessary. US Oncology corporate pharmacists reviewed the recommendations and discussed findings with an oversight committee. Final proposals were voted on before being incorporated into iKnowMed. An internal database tracking system tool for all reviewed recommendations was created to track and communicate needed changes to the electronic health record. RESULTS Out of 511 regimen order sets, 51 were recommended for removal or consolidation. Of the remaining 460 regimen order sets, all had some administrative changes. Specifically, 75% had title changes, 14% had cycle-related changes, 31% had reference updates, and 13% had dosing updates. CONCLUSION Electronic health records systems, such as iKnowMed, can provide standardized order sets for a large oncology network. However, the regimens need to be evaluated routinely using standardized procedures to ensure they are accurate and current.
Collapse
|
3
|
Newton C, Fetter A, Bashey R, Jimenez S. Clinical Studies and Pathological Changes in Articular Cartilage in Experimental Canine Osteoarthritis and Effects of the In Vivo Administration of a Glycosaminoglycanpeptide (GAG-Peptidecomplex) from Bone Marrow and Cartilage. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1048131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Peters M, Dasilva A, Weckermann D, Oberneder R, Ebner B, Kirchinger P, Fetter A, Köhne-Volland R, Baeuerle P, Gjorstrup P. Phase I study of the novel fully human monoclonal antibody MT201, directed against epithelial cellular adhesion molecule (Ep-CAM), in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Peters
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - A. Dasilva
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - D. Weckermann
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - R. Oberneder
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - B. Ebner
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - P. Kirchinger
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - A. Fetter
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - R. Köhne-Volland
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - P. Baeuerle
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| | - P. Gjorstrup
- Micromet AG, München, Germany; Augsburg Hospital, Augsburg, Germany; Klinikum Planegg, Planegg, Germany; Metronomia AG, München, Germany
| |
Collapse
|
5
|
Pedneault L, Brothers C, Pagano G, Tymkewycz P, Yeo J, Millard J, Fetter A. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther 2000; 22:1378-94; discussion 1377. [PMID: 11192131 DOI: 10.1016/s0149-2918(00)83038-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Amprenavir (APV) is a new HIV-I protease inhibitor used in combination with other antiretroviral agents for the treatment of HIV-1 infection. OBJECTIVE The aim of this study was to assess the safety profile and tolerability of APV. METHODS A review of data from 358 adults enrolled in 2 phase III, randomized, 48-week, controlled studies and from 268 children enrolled in 1 phase II and 1 phase III study was conducted. The adult data were collected between February 25, 1997, and April 1, 1999. Data were collected in children from September 10, 1997, to January 15, 1999; these data were collected before completion of either study. Adults and children who had and had not been treated previously with antiretroviral agents were enrolled. In these studies, APV was used in combination with 2 nucleoside reverse transcriptase inhibitors. RESULTS The most common drug-related adverse events in patients receiving APV were gastrointestinal events and oral/perioral paresthesia. The majority of adverse events were mild or moderate in intensity, early in onset, and transient. Nausea (27/358 patients, 8%), vomiting (15/358, 4%), rash (11/358, 3%), and diarrhea/loose stools (9/358, 3%) were the most common adverse events associated with treatment discontinuation. Severe laboratory abnormalities possibly related to APV were rare. In children, the nature and frequency of adverse events were similar to those in adults. Metabolic complications were infrequent in APV studies to date; symptoms related to fat redistribution were reported in <3% of patients treated with APV. Lipid or glucose laboratory abnormalities were reported with similar frequency in the APV and control groups in both studies in adults. CONCLUSIONS In the clinical trials reviewed, APV was generally well tolerated when administered with other antiretroviral agents in adult and pediatric patients with HIV infection.
Collapse
Affiliation(s)
- L Pedneault
- Glaxo Wellcome HIV and Opportunistic Infections Clinical Development, Research Triangle Park, North Carolina, USA
| | | | | | | | | | | | | |
Collapse
|
6
|
Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS 1999; 13:2411-20. [PMID: 10597783 DOI: 10.1097/00002030-199912030-00013] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To determine the safety and efficacy of amprenavir (APV) in combination with lamivudine (3TC) and zidovudine (ZDV). DESIGN Multicenter, randomized, partially blinded trial. SETTING Nine study sites in the United States and Europe. PATIENTS A group of 84 HIV-infected subjects with no prior 3TC or protease inhibitor therapy experience, CD4 cell count > or = 150 x 10(6) cells/l, and plasma HIV RNA > 10000 copies/ml. INTERVENTIONS 3TC/ZDV with one of three doses of APV (900, 1050, or 1200 mg) versus 3TC/ZDV with 1050 mg placebo. All medications were dosed twice daily. The 1050 mg placebo and the APV 1050 mg dose were administered blinded. After 12 weeks, APV 1050 mg was substituted for 1050 mg placebo in the control group and the blind was maintained. MAIN OUTCOME MEASURES Reduction in plasma HIV RNA from baseline; proportion of subjects with plasma HIV RNA < 400 copies/ml; and an increase in CD4 cell count from baseline. RESULTS During the initial 12-week study period, APV/3TC/ZDV-treated subjects had greater viral suppression than the group receiving two nucleosides. By 48 weeks, 89% of subjects in the group taking the highest APV dose (1200 mg) had plasma HIV RNA < 400 copies/ml while 42% of the 900 mg group and 60% of the 3TC/ZDV group (1050 mg APV added at week 12) had plasma HIV RNA < 400 copies/ml using an as-treated analysis. By 60 weeks, 86% of subjects in the APV 1200 mg group had plasma HIV RNA < 400 copies/ml in the as-treated analysis, while 25% (900 mg), 43% (1050 mg), and 20% (1200 mg) of subjects had viral load <400 copies/ml in a strict intent-to-treat analysis owing to treatment discontinuations. Median CD4 cell count increases at week 60 were highest for the three treatment groups who received APV throughout the study, by intent-to-treat and as-treated analyses. The most common adverse events considered to be possibly drug related were nausea, rash, oral paresthesia, diarrhea, and fatigue. CONCLUSIONS Treatment with APV, dosed at 1200 mg twice daily in combination with 3TC/ZDV, resulted in sustained viral suppression. This combination represents a potent alternative initial antiretroviral regimen for protease inhibitor-naive individuals.
Collapse
|
7
|
Abstract
Many studies have focused on the epidemiology and pathogenesis of oral candidiasis in HIV infection. Little is known on the incidence and predisposing factors of asymptomatic oral candida carriage in this setting, obviously an important issue in view of prophylaxis. To address this question, 261 consecutive HIV-infected individuals without clinical evidence of candidiasis were investigated. C. albicans was isolated from cultured oral cavity swabs of 63 subjects (24%). Colonization was significantly more frequent in IV drug users, CDC groups IV, and in subjects with lymphocytopenia, CD4+ cell depletion, or elevated beta-2 microglobulin. These data further suggest that oral candidiasis occurs in HIV infection as a result of C. albicans overgrowth and raise the question of primary antifungal prophylaxis in subjects with low CD4 counts and asymptomatic oral Candida carriage.
Collapse
Affiliation(s)
- A Fetter
- Centre d'Information et de Soins de I'immunodéficience Humaine, Hôpitaux Universitaires de Strasbourg, France
| | | | | | | | | |
Collapse
|